Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2010 |
| End Date: | March 2012 |
An Extension of Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Pegylated Interferon and Ribavirin After Completing Treatment in a Phase 2 Study and Have Relapsed After at Least 44 Weeks Tx With Peg-IFN and RBV.
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited
to participate in this extension study if they complete treatment in study
SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV.
In this extension study, subjects will be asked to give permission to share their HCV RNA
viral load test results, obtained from local laboratories, at the different time points and
will also be asked to give permission to share their SOC dosing information (peg-IFN and
RBV). As no SCV-07 treatment, procedures, or assessments will be required during this
extension study, no related safety information will be collected.
The study will last up to 72 weeks after subjects complete treatment on study
SCI-SCV-HCV-P2-001 and begin retreatment with peg-IFN and RBV.
We found this trial at
4
sites
Click here to add this to my saved trials
University of Cincinnati Medical Center Opening in 1823 as the country
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials